Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants Read more about Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
An Open Label Study of CM-AT for the Treatment of Children With Autism Read more about An Open Label Study of CM-AT for the Treatment of Children With Autism
Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD Read more about Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD
Safety & Effectiveness Study of AEGEA Vapor System to Treat Excessive Uterine Bleeding Read more about Safety & Effectiveness Study of AEGEA Vapor System to Treat Excessive Uterine Bleeding
A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone Read more about A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain Read more about A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes Read more about A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus Read more about A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) Read more about ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)